Relin has started independent research and development many years ago. By entrusting high-level CROs at home and abroad, collaborating in research and development, and adopting a strategy of combining direct technology introduction, it quickly integrates various technical resources, forming a competitive and open product development model, building excellent product pipeline development capabilities, and realizing commercialization through entrusting CMO production for all products. Currently, the company's research and development pipeline is rich and covers fields such as ophthalmology, otolaryngology, etc. Multiple products are already in the stages of registration evaluation and development. The company has many high-level qualifications such as Specialized, Refinement, Differential, and Innovation Enterprise (SRDI Enterprise), Innovative Enterprise, and High-tech Enterprise, which fully prove that the company is a high-quality enterprise with strong innovation ability, focus on segmented market, and good growth potential.
The company has an efficient and professional R&D and project management team, covering functions such as pharmaceutical development, pharmacology, clinical medicine, quality management, and drug registration. The core R&D personnel have many years of work experience in drug development and registration.
With the implementation of the new version of the Drug Administration Law on December 1, 2019, Relin began to embark on the path of becoming a Drug Marketing Authorization Holder (MAH), establishing a quality management system covering the entire lifecycle of drug development, registration, production, pharmacovigilance (PV), etc. and setting up a specialized quality management department. In 2021, the company obtained the Drug Manufacturing Certificate (Certificate B), and started the role of MAH(Marketing Authorization Hold.
Relin's first product with independent intellectual property right, "Zuofu" (Levofloxacin Ear Drops), obtained the New Drug Certificate and the Drug Registration Approval in 2009. It has been on the market for many years and has remained the top-selling product in the market. The first MAH product, "Huiming" (Levofloxacin Eye Drops), obtained the Drug Registration Approval in 2021.
Home >